IL152554A0 - PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII - Google Patents

PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII

Info

Publication number
IL152554A0
IL152554A0 IL15255401A IL15255401A IL152554A0 IL 152554 A0 IL152554 A0 IL 152554A0 IL 15255401 A IL15255401 A IL 15255401A IL 15255401 A IL15255401 A IL 15255401A IL 152554 A0 IL152554 A0 IL 152554A0
Authority
IL
Israel
Prior art keywords
factor
pharmaceutical composition
xiii
viia
factor viia
Prior art date
Application number
IL15255401A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL152554A0 publication Critical patent/IL152554A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL15255401A 2000-05-10 2001-05-10 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII IL152554A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200000771 2000-05-10
DKPA200000778 2000-05-10
DKPA200000871 2000-06-06
PCT/DK2001/000322 WO2001085198A1 (en) 2000-05-10 2001-05-10 tHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIA AND A FACTOR XIII

Publications (1)

Publication Number Publication Date
IL152554A0 true IL152554A0 (en) 2003-05-29

Family

ID=27222387

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15255401A IL152554A0 (en) 2000-05-10 2001-05-10 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII

Country Status (17)

Country Link
US (3) US20030092627A1 (hu)
EP (3) EP1282439B1 (hu)
JP (2) JP2003532684A (hu)
CN (1) CN1304049C (hu)
AT (2) ATE300953T1 (hu)
AU (3) AU5822801A (hu)
BR (1) BR0110659A (hu)
CA (1) CA2406583A1 (hu)
CZ (1) CZ20023667A3 (hu)
DE (2) DE60112429T2 (hu)
DK (1) DK1282438T3 (hu)
ES (2) ES2254414T3 (hu)
HU (1) HUP0301868A3 (hu)
IL (1) IL152554A0 (hu)
NO (1) NO20025355L (hu)
PL (1) PL365042A1 (hu)
WO (2) WO2001085199A1 (hu)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0014486A (pt) * 1999-10-04 2002-09-17 Chiron Corp Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP2226385B1 (en) * 2000-09-13 2013-07-10 Novo Nordisk Health Care AG Human Coagulation Factor VII Variants
CZ2003611A3 (cs) 2000-09-13 2003-08-13 Novo Nordisk A/S Varianty lidského koagulačního faktoru VII
ES2282319T3 (es) * 2000-11-03 2007-10-16 Zymogenetics, Inc. Uso de factor xiii de coagulacion sanguinea para tratar la hemofilia a.
US7173000B2 (en) 2000-11-09 2007-02-06 The Scripps Research Institute Modified factor VIIa
ES2288524T3 (es) * 2000-11-10 2008-01-16 Zymogenetics, Inc. Factor xiii en combinacion con factor ix para tratar la hemofilia b.
ES2301624T3 (es) * 2001-02-05 2008-07-01 Novo Nordisk Health Care Ag Uso combinado de polipeptidos de factor vii y polipeptidos de factor viii.
JP2004521129A (ja) * 2001-02-21 2004-07-15 ザイモジェネティクス，インコーポレイティド フォン・ヴィレブランド病の処理方法
EP1425034A4 (en) * 2001-09-10 2005-09-21 Zymogenetics Inc METHOD FOR THE TREATMENT OF CUMARIN-INDUCED BLEEDING
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
EP1446147A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
IL162239A0 (en) 2001-12-21 2005-11-20 Novo Nordisk Healthcare Ag Liquid composition of factor vii polypeptides
KR101006070B1 (ko) * 2001-12-21 2011-01-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 인자 ⅶ 폴리펩티드의 액체 조성물
WO2004000347A1 (en) 2002-06-21 2003-12-31 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2004062689A1 (en) 2003-01-08 2004-07-29 Chiron Corporation Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
JP4658041B2 (ja) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドの液体組成物
JP5653572B2 (ja) 2003-08-14 2015-01-14 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの液状水性医薬組成物
CN101870729A (zh) 2003-09-09 2010-10-27 诺和诺德医疗保健公司 凝固因子ⅶ多肽
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas
WO2005115442A1 (en) * 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
EP1784415A2 (en) * 2004-08-27 2007-05-16 Novo Nordisk Health Care AG Purification of factor xiii polypeptides from biological materials
MX2007002903A (es) * 2004-09-10 2007-07-11 Pharmaorigin Aps Metodos para el tratamiento de hemoptisis o hemorragias traqueales, bronquiales o alveolares, locales.
EP1817339B1 (en) 2004-11-23 2012-01-11 ZymoGenetics, Inc. Purification of recombinant human factor xiii
EP1855712A2 (en) * 2005-02-28 2007-11-21 Novo Nordisk Health Care AG Fxiii variants with improved properties
US20080161425A1 (en) * 2005-07-29 2008-07-03 Universiteit Van Maastricht Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor
WO2007104317A1 (en) * 2006-03-16 2007-09-20 Drugrecure Aps Methods for local treatment with factor vii
JP2009543841A (ja) * 2006-07-17 2009-12-10 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
EP2481797A1 (en) * 2007-04-13 2012-08-01 Catalyst Biosciences, Inc. Modified factor VII polypeptides and uses thereof
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
KR101897534B1 (ko) 2008-04-21 2018-09-12 노보 노르디스크 헬스 케어 악티엔게젤샤프트 건조한 트랜스글루타미나제 조성물
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
NZ607892A (en) 2008-12-19 2014-11-28 Baxter Int Tfpi inhibitors and methods of use
EP2547355B1 (en) 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
CN103179982A (zh) 2010-08-05 2013-06-26 科学与工业研究委员会 具有溶血栓和抗凝血性质的蛋白融合构建体
NZ629130A (en) 2012-03-21 2016-10-28 Baxalta Inc Tfpi inhibitors and methods of use
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
JP6559188B2 (ja) * 2017-07-06 2019-08-14 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) * 2017-09-04 2018-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018108089A (ja) * 2018-02-19 2018-07-12 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
US20210263052A1 (en) 2018-07-25 2021-08-26 Sony Corporation Blood coagulation system analysis device
JP6848016B2 (ja) * 2019-07-16 2021-03-24 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221780A (en) * 1978-12-04 1980-09-09 Cort Joseph H Method for producing high potency factor VIII
CA1281647C (en) * 1985-11-26 1991-03-19 Novo Nordisk A/S Compositions and methods for the treatment of bleeding disorders
US5622988A (en) * 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK261490D0 (da) * 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
CZ83194A3 (en) * 1991-10-11 1994-11-16 Novo Nordisk As Haemostatic preparation for inducing blood precipitation on a bleeding wound
CA2127107C (en) * 1991-12-31 2007-06-19 Bruce L. A. Carter Methods and compositions for reducing blood loss
AU4784693A (en) * 1992-07-24 1994-02-14 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
DE4429118C2 (de) * 1994-08-17 1997-01-16 Siemens Ag Radarsensor
EP0885020A1 (en) * 1996-02-20 1998-12-23 Cohesion Corporation Tissue sealant compositions and methods of use thereof
AU7907398A (en) * 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
CA2318434A1 (en) * 1997-12-23 1999-07-01 Nuvas Llc Thrombogenic polypeptide chimeras and conjugates having activity dependent upon association with tumor vascular endothelium
JP2002514433A (ja) * 1998-05-14 2002-05-21 バッテル メモリアル インスティテュート トランスジェニック植物由来ヒト凝血因子
EP1148427A1 (en) * 2000-04-21 2001-10-24 Koninklijke KPN N.V. Method of and system for creating a button type bookmark in a web browser displaying a user-selected part of the corresponding data file
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
US6825323B2 (en) * 2001-01-10 2004-11-30 The United States Of America As Represented By The Secretary Of The Army Compositions for treatment of hemorrhaging with activated factor VIIa in combination with fibrinogen and methods of using same
ES2301624T3 (es) * 2001-02-05 2008-07-01 Novo Nordisk Health Care Ag Uso combinado de polipeptidos de factor vii y polipeptidos de factor viii.
US20030203845A1 (en) * 2001-02-05 2003-10-30 Knudsen Jens Bjerre Combined use of factor VII polypeptides and factor IX polypeptides
US7419949B2 (en) * 2001-07-16 2008-09-02 Novo Noridsk Healthcare A/G Single-dose administration of factor VIIa
US20030119741A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides
US20060025336A1 (en) * 2001-07-16 2006-02-02 Novo Nordisk A/S Pharmaceutical compositions comprising combinations of factor VII polypeptides and aprotinin polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
US7291587B2 (en) * 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
US7078479B2 (en) * 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
US20030119743A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors
US20030119723A1 (en) * 2001-11-09 2003-06-26 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides
JP2005526004A (ja) * 2001-11-09 2005-09-02 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよびトラネキサム酸を含む薬学的組成物
US20030124118A1 (en) * 2001-11-27 2003-07-03 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and protein S inhibitors
US7125846B2 (en) * 2001-11-09 2006-10-24 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides
JP2006510568A (ja) * 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物

Also Published As

Publication number Publication date
BR0110659A (pt) 2003-02-11
ES2247106T3 (es) 2006-03-01
DE60115422D1 (de) 2006-01-05
WO2001085199A1 (en) 2001-11-15
EP1282439A1 (en) 2003-02-12
PL365042A1 (en) 2004-12-27
ATE300953T1 (de) 2005-08-15
EP1593389A1 (en) 2005-11-09
CN1429117A (zh) 2003-07-09
ES2254414T3 (es) 2006-06-16
EP1282438A1 (en) 2003-02-12
AU5822801A (en) 2001-11-20
HUP0301868A3 (en) 2006-11-28
WO2001085198A1 (en) 2001-11-15
EP1282439B1 (en) 2005-11-30
CZ20023667A3 (cs) 2003-04-16
HUP0301868A2 (hu) 2003-08-28
JP2004505016A (ja) 2004-02-19
JP2003532684A (ja) 2003-11-05
ATE311198T1 (de) 2005-12-15
CA2406583A1 (en) 2001-11-15
NO20025355D0 (no) 2002-11-08
US20060199766A1 (en) 2006-09-07
DE60112429T2 (de) 2006-06-01
US20070280920A1 (en) 2007-12-06
EP1282438B1 (en) 2005-08-03
AU2001258230A1 (en) 2001-11-20
DK1282438T3 (da) 2005-11-14
AU2001258228B2 (en) 2006-01-12
CN1304049C (zh) 2007-03-14
NO20025355L (no) 2003-01-09
US20030092627A1 (en) 2003-05-15
DE60112429D1 (de) 2005-09-08
DE60115422T2 (de) 2006-08-17

Similar Documents

Publication Publication Date Title
IL152554A0 (en) PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII
HRP20030046A2 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
AU6751101A (en) Topical agent for dermatological use
GB9907461D0 (en) Neurite regeneration
HK1068106A1 (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
EP1404281A4 (en) TOPICAL USE PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SKIN AND / OR MUCOSAL LESIONS, USE OF COMPOSITIONS AND COMPOUNDS IN THE TREATMENT OF SKIN AND / OR MUCOUS DISEASES
EP1037918A4 (en) METHOD AND COMPOSITIONS FOR INCREASING THE EFFICIENCY OF VACCINALS USING CHEMOKINES
HK1032534A1 (en) L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof
AU2002210491A1 (en) Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof
HUP0303936A3 (en) Novel composition and use
WO2001022917A8 (en) Effervescent compositions comprising nimesulide
IT1319685B1 (it) Formulazioni alimentari ad elevato contenuto di calcio.
HUP0002154A3 (en) Use of famotidine for the preparation of pharmaceutical compositions treating depression or symptoms related with depression
GB0007217D0 (en) Materials and methods relating to the treatment of leukaemias
WO2001060344A3 (en) Use of thiamphenicol in the treatment of vancomycin-intermediates and multiresistant staphylococci infections
AU2002237251A1 (en) A pharmaceutical composition containing benzopyrano-oxopyrimidotetrahydrothiazine and its use in the treatment of hiv
SI1313489T1 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
HK1054873A1 (en) Pharmaceutical composition based on cocaethylene and use thereof for treating psychoactive substancedependence
AUPR611201A0 (en) A composition for use in prophylaxis and/or treatment
ZA200208695B (en) Pharmaceutical composition comprising factor VIIa and factor XIII.
CA96622S (en) Pouch, primarily containing cleaning composition(s), fabric care composition(s) or the like
GB0004648D0 (en) Compositions and mixtures for the treatment of skin
MX9709941A (es) Nueva composicion farmaceutica con efecto anestesico.